Milani Morteza, Sharifi Yaeghob, Rahmati-Yamchi Mohammad, Somi Mohammad H, Akbarzadeh Abolfazl
Liver and Gastrointestinal disease research center, Tabriz University of Medical Sciences, Tabriz, Iran.
Expert Rev Vaccines. 2015 Jun;14(6):833-40. doi: 10.1586/14760584.2015.1008460. Epub 2015 Feb 3.
Helicobacter pylori infection is very common worldwide and is an important cause of gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma. Since the eradication requires treatment with multidrug regimens, prevention of primary infection by a suitable vaccine is attractive. Developing vaccines on the spot when and where an infection is breaking out might be possible, thanks to engineered nanoparticles. In this review, the nature of the host immune response to H. pylori infection is considered. We explain recent candidate vaccines and prophylactic or therapeutic immunization strategies for use against H. pylori. We also describe identification of different types of immune responses that may be related to protection against H. pylori infection. Thus, it seems that there is still a strong need to clarify the main protective immune response against H. pylori.
幽门螺杆菌感染在全球非常普遍,是胃炎、消化性溃疡病、胃黏膜相关淋巴组织淋巴瘤和胃腺癌的重要病因。由于根除需要使用多药方案进行治疗,因此通过合适的疫苗预防原发性感染很有吸引力。借助工程化纳米颗粒,在感染爆发的当时当地研发疫苗或许是可行的。在这篇综述中,我们考虑了宿主对幽门螺杆菌感染的免疫反应的本质。我们解释了近期用于对抗幽门螺杆菌的候选疫苗以及预防性或治疗性免疫策略。我们还描述了可能与预防幽门螺杆菌感染相关的不同类型免疫反应的识别。因此,似乎仍迫切需要阐明针对幽门螺杆菌的主要保护性免疫反应。